Dyadic International stock (US26746E1055): Hantavirus collaboration with Scripps puts C1 platform in focus

Dyadic International shares on Nasdaq are reacting to a fresh collaboration with Scripps Research, announced on 05/28/2026, to develop rapid-response monoclonal antibody and vaccine candidates against hantaviruses using the company’s C1 expression platform.

Dyadic International, a United States-based biotechnology specialist listed on Nasdaq under the ticker DYAI, moved into the spotlight on 05/28/2026 after announcing a new research collaboration with Scripps Research focused on rapid-response monoclonal antibody and vaccine development targeting hantaviruses, including the Andes virus strain associated with Hantavirus Pulmonary Syndrome, according to a Form 8-K filing on the same date and accompanying press material from the company and Scripps.SEC filing via StockTitan as of 05/28/2026MarketScreener as of 05/28/2026

In the United States home market, Dyadic International trades on Nasdaq in USD, with MarketScreener data showing a last close of around USD 0.76 and a daily change of roughly -1.7% for DYAI at the time of the collaboration news, underlining how the new research initiative arrives against the backdrop of a small-cap biotech working to monetize its C1 cell line technology across vaccines, therapeutics and non-pharmaceutical applications.MarketScreener as of 05/28/2026

As of: 05/28/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: DYAI
• Sector/industry: Biotechnology - protein expression and vaccine platforms
• Headquarters/country: Jupiter, United States
• Core markets: North America, Europe, selected global biotech and pharma customers
• Key revenue drivers: Licensing of C1 expression technology, research collaborations, and development services for recombinant proteins, vaccines and enzymes
• Home exchange/listing venue: Nasdaq (DYAI)
• Trading currency: USD

Dyadic International: core business model

Dyadic International focuses on commercializing its proprietary C1 fungal expression platform by partnering with pharmaceutical, biotech and industrial players that use engineered microbes to produce recombinant proteins for vaccines, biologic drugs, enzymes and other specialty applications.MarketScreener company profile as of 05/28/2026

Industry trends and competitive position

The collaboration with Scripps Research highlights a broader trend in the biotechnology industry toward platform technologies aimed at rapid pandemic and outbreak response, with Dyadic positioning its C1 expression system as a scalable, high-productivity alternative to traditional mammalian cell culture for vaccines and antibodies, according to the 05/28/2026 collaboration announcement that emphasizes rapid development and large-scale biologic manufacturing.SEC filing via StockTitan as of 05/28/2026FirstWord Pharma as of 05/28/2026

Sector commentary in the collaboration coverage notes that Dyadic had already generated preclinical data showing C1-produced Andes virus monoclonal antibodies with binding and neutralization characteristics comparable to mammalian cell-produced antibodies, and that the company has previously supported GMP manufacturing and a Phase 1 clinical evaluation using the C1 platform, suggesting that Dyadic competes in a niche of microbial-based expression platforms seeking acceptance for human vaccines and biologics alongside more established mammalian systems.FirstWord Pharma as of 05/28/2026Pluang as of 05/28/2026

Conclusion

The 05/28/2026 announcement that Dyadic International and Scripps Research will collaborate on rapid-response hantavirus antibodies and vaccines underscores the company’s strategy of advancing its C1 platform through targeted infectious-disease partnerships and highlights the continuing role of US-based academic alliances in validating alternative expression systems for pandemic preparedness. For investors tracking Nasdaq-listed small-cap biotech names, the project provides a fresh data point on Dyadic’s ability to translate its technology into concrete development programs while operating in a competitive field of vaccine and biologics platforms that must prove scalability, regulatory acceptance and commercial potential over time.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.